Epidemic Hepatitis B Caused by Commercial Human Immunoglobulin

John, Thomas; Rajagopalan, M. S.; Ninan, George T.; Frederick, John; Flewett, T. H.; Francis, Donald P.; Zuckerman, Arie J.

doi:10.1016/s0140-6736(79)92964-7

Cited by 47 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, jaundice appears only in about 1 out of 3 individuals [16,17,18], but some HBV strains might be particularly virulent. In one recent outbreak attributed to an inadequately shared glucose-monitoring device, 6 out of 8 elderly patients contracting hepatitis B died from acute hepatitis B [19].…”

Section: Natural Course Of Acute Hepatitis B Virus Infectionmentioning

confidence: 99%

Therapy of Acute and Fulminant Hepatitis B

Tillmann

Patel

2014

Intervirology

View full text Add to dashboard Cite

Although new hepatitis B virus (HBV) infections are decreasing due to improving vaccination coverage, patients without vaccination coverage can still suffer from manifestation of acute hepatitis B with jaundice and (although rarely) liver failure. No treatment is indicated for mild acute hepatitis B; however, antiviral therapy should be initiated for patients showing signs of significant liver impairment as exemplified by deterioration of prothrombin time to an equivalent of 1.5 or 50% of the ‘Quick test'. For fulminant hepatitis, there is no complete agreement on whether antiviral treatment would alter the course, but it should still be started, as it would reduce the risk of reinfection in case there is a need for liver transplantation. Patients in danger of progression towards acute liver failure should be referred to transplant centers as early as possible.

show abstract

Section: Natural Course Of Acute Hepatitis B Virus Infectionmentioning

confidence: 99%

Therapy of Acute and Fulminant Hepatitis B

Tillmann

Patel

2014

Intervirology

View full text Add to dashboard Cite

show abstract

“…Since the initial clinical use of immunoglobulin G (IgG) concentrates of human origin, transmission of pathogens and non-infectious adverse events (AEs) were reported ( 1 – 7 ). Before the mid 90s, transmission of pathogens depended on the pool size and the fractionation methods used, particularly the polishing steps of an IgG concentrate ( 8 ).…”

Section: Introduction – the Tinge Of The Dark Side Of Therapies With mentioning

confidence: 99%

On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events

et al. 2015

View full text Add to dashboard Cite

Therapy by human immunoglobulin G (IgG) concentrates is a success story ongoing for decades with an ever increasing demand for this plasma product. The success of IgG concentrates on a clinical level is documented by the slowly increasing number of registered indication and the more rapid increase of the off-label uses, a topic dealt with in another contribution to this special issue of Frontiers in Immunology. A part of the success is the adverse event (AE) profile of IgG concentrates which is, even at life-long need for therapy, excellent. Transmission of pathogens in the last decade could be entirely controlled through the antecedent introduction by authorities of a regulatory network and installing quality standards by the plasma fractionation industry. The cornerstone of the regulatory network is current good manufacturing practice. Non-infectious AEs occur rarely and mainly are mild to moderate. However, in recent times, the increase in frequency of hemolytic and thrombotic AEs raised worrying questions on the possible background for these AEs. Below, we review elements of non-infectious AEs, and particularly focus on hemolysis and thrombosis. We discuss how the introduction of plasma fractionation by ion-exchange chromatography and polishing by immunoaffinity chromatographic steps might alter repertoire of specificities and influence AE profiles and efficacy of IgG concentrates.

show abstract

Inactivation of the Hutchinson strain of hepatitis non‐A, non‐B virus in intravenous immunoglobulin by β‐propiolactone

Stephan

Dichtelmüller

Prince

et al. 1988

Journal of Medical Virology

View full text Add to dashboard Cite

beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). Two chimpanzees were inoculated with a beta-PL-treated immunoglobulin solution to which this dose of the titrated virus had been added prior to beta-PL treatment. beta-PL treatment was performed in accordance with the production procedure used for a licensed intravenous immunoglobulin preparation. Neither animal developed hepatitis. When subsequently challenged with the same spiked immunoglobulin solution that had not been beta-PL treated, both animals developed clear-cut hepatitis non-A, non-B. The results of this experiment demonstrate that beta-PL treatment is effective for the inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulin.

show abstract

Epidemic Hepatitis B Caused by Commercial Human Immunoglobulin

Cited by 47 publications

References 6 publications

Therapy of Acute and Fulminant Hepatitis B

Therapy of Acute and Fulminant Hepatitis B

On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events

Inactivation of the Hutchinson strain of hepatitis non‐A, non‐B virus in intravenous immunoglobulin by β‐propiolactone

Contact Info

Product

Resources

About